These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 32178745)
21. Molecular Behavior of α-Synuclein Is Associated with Membrane Transport, Lipid Metabolism, and Ubiquitin-Proteasome Pathways in Lewy Body Disease. Kon T; Lee S; Martinez-Valbuena I; Yoshida K; Tanikawa S; Lang AE; Kovacs GG Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473923 [TBL] [Abstract][Full Text] [Related]
22. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Hashimoto M; Masliah E Brain Pathol; 1999 Oct; 9(4):707-20. PubMed ID: 10517509 [TBL] [Abstract][Full Text] [Related]
23. A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease. Smith BR; Nelson KM; Kemper LJ; Leinonen-Wright K; Petersen A; Keene CD; Ashe KH Acta Neuropathol Commun; 2019 Jul; 7(1):124. PubMed ID: 31362787 [TBL] [Abstract][Full Text] [Related]
24. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Rockenstein E; Hansen LA; Mallory M; Trojanowski JQ; Galasko D; Masliah E Brain Res; 2001 Sep; 914(1-2):48-56. PubMed ID: 11578596 [TBL] [Abstract][Full Text] [Related]
25. Modeling Lewy body disease with Jin Y; Li F; Li Z; Ikezu TC; O'Leary J; Selvaraj M; Zhu Y; Martens YA; Koga S; Santhakumar H; Li Y; Lu W; You Y; Lolo K; DeTure M; Beasley AI; Davis MD; McLean PJ; Ross OA; Kanekiyo T; Ikezu T; Caulfield T; Carr J; Wszolek ZK; Bu G; Dickson DW; Zhao N Sci Adv; 2024 Sep; 10(37):eadk3700. PubMed ID: 39259788 [TBL] [Abstract][Full Text] [Related]
26. Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease. Barba L; Abu-Rumeileh S; Barthel H; Massa F; Foschi M; Bellomo G; Gaetani L; Thal DR; Parnetti L; Otto M Brain; 2024 Oct; 147(10):3325-3343. PubMed ID: 38991041 [TBL] [Abstract][Full Text] [Related]
27. The genetics of dementia with Lewy bodies: what are we missing? Meeus B; Theuns J; Van Broeckhoven C Arch Neurol; 2012 Sep; 69(9):1113-8. PubMed ID: 22635379 [TBL] [Abstract][Full Text] [Related]
28. Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Barrachina M; Castaño E; Dalfó E; Maes T; Buesa C; Ferrer I Neurobiol Dis; 2006 May; 22(2):265-73. PubMed ID: 16380264 [TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Beyer K; Domingo-Sábat M; Lao JI; Carrato C; Ferrer I; Ariza A Neurogenetics; 2008 Feb; 9(1):15-23. PubMed ID: 17955272 [TBL] [Abstract][Full Text] [Related]
30. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331 [TBL] [Abstract][Full Text] [Related]
31. Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. Giil LM; Aarsland D J Alzheimers Dis; 2020; 73(4):1321-1330. PubMed ID: 31903991 [TBL] [Abstract][Full Text] [Related]
32. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Tsuang D; Leverenz JB; Lopez OL; Hamilton RL; Bennett DA; Schneider JA; Buchman AS; Larson EB; Crane PK; Kaye JA; Kramer P; Woltjer R; Kukull W; Nelson PT; Jicha GA; Neltner JH; Galasko D; Masliah E; Trojanowski JQ; Schellenberg GD; Yearout D; Huston H; Fritts-Penniman A; Mata IF; Wan JY; Edwards KL; Montine TJ; Zabetian CP Neurology; 2012 Nov; 79(19):1944-50. PubMed ID: 23035075 [TBL] [Abstract][Full Text] [Related]